Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Mark Timney
AddedMar 31, 2024
UpdatedMay 31, 2026
Mark Timney

Mark Timney

Board Member, Blade Therapeutics

CrunchbaseLinkedIn

Mark Timney's Career

Blade Therapeutics
Blade Therapeutics

South San Francisco, CA, US

Board Member· Board
Attralus
Attralus

San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Mark Timney's Career

Blade Therapeutics
Blade Therapeutics
Series D$51.5M282013South San Francisco, CA, US
Board Member· Board

Leadership at Blade Therapeutics

Wendye RobbinsWendye RobbinsCEO
Jim ScopaJim ScopaBoard Member
Rana Al-HallaqRana Al-HallaqBoard Member
Luke EvninLuke EvninBoard Member
Peter Van VlasselaerPeter Van VlasselaerBoard Member
Harry DietzHarry DietzFounder

Similar to Blade Therapeutics

Pliant TherapeuticsPliant TherapeuticsSouth San Francisco, CA, USTherapeuticsest. 2015Pliant TherapeuticsSouth San Francisco, CA, US · est. 2015

Pliant Therapeutics: A California-based biopharmaceutical company innovating therapies for fibrotic diseases.

Public · $694.9M124
SphynKx TherapeuticsSphynKx TherapeuticsCharlottesville, VA, USBiotechnology, Therapiesest. 2010SphynKx TherapeuticsCharlottesville, VA, US · est. 2010

SphynKx Therapeutics: Innovating biotech solutions for cancer and fibrosis treatment.

Seed · $50k30
Mistral TherapeuticsMistral TherapeuticsSan Diego, CA, USFibrosis Treatmentsest. 2011Mistral TherapeuticsSan Diego, CA, US · est. 2011

Mistral Therapeutics: A San Diego-based biotech firm specializing in innovative fibrosis treatments.

Series B · $36.4M6
BLR BioBLR BioKenosha, WI, USBiologics, Diagnosticsest. 2013BLR BioKenosha, WI, US · est. 2013

Kenosha-based BLR Bio, a private biotech firm, specializes in orphan and specialty fibrotic diseases.

Pre-Seed · $780k5
Attralus
Attralus
Series B$141.2M292019San Francisco, CA, US
Board Member· Board

Leadership at Attralus

Jake BauerJake BauerBoard Member
Jonathan WallJonathan WallCo-Founder
Richard GasterRichard GasterBoard Member
Spencer GuthrieSpencer GuthrieFounder & CEO

Similar to Attralus

AltPepAltPepSeattle, WA, USBiotech, Therapeuticsest. 2018AltPepSeattle, WA, US · est. 2018

AltPep: A biomedical startup innovating in amyloid disease treatment, focusing on Alzheimer's.

Series B · $76M24
Aurion BiotechAurion BiotechSeattle, WA, USBiotech, Therapiesest. 2021Aurion BiotechSeattle, WA, US · est. 2021

Aurion Biotech: Clinical-stage biotech firm pioneering advanced therapies to cure blindness.

Late Stage Private · $120M55
AdrxAdrxThousand Oaks, CA, USDrug Discoveryest. 2013AdrxThousand Oaks, CA, US · est. 2013

ADRx, Inc.: A California-based biopharmaceutical firm innovating novel drugs for amyloid diseases.

Series A · $24.3M9
Amylyx PharmaceuticalsAmylyx PharmaceuticalsCambridge, MA, USTherapeuticsest. 2014Amylyx PharmaceuticalsCambridge, MA, US · est. 2014

Amylyx Pharmaceuticals: A global biopharmaceutical firm innovating therapies for ALS and neurodegenerative diseases.

Public · $448.5M262

Mark Timney's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · Kakao

People Similar to Mark Timney

Nancy BriefsNancy BriefsBoard Member · New View SurgicalBen ScruggsBen ScruggsBoard Member · Veralox TherapeuticsTimothy WojciechowskiTimothy WojciechowskiCEO · Aatru MedicalSteven WattSteven WattCEO · Atterx BioTherapeuticsNathaniel Justin KanNathaniel Justin KanBoard Member · ZerocaterMark SantacroseMark SantacroseBoard Member · Tecta America